英国全科医疗记录中胃轻瘫的流行病学与结局
基于英国临床实践研究数据链(CPRD)的回顾性横断面研究,评估胃轻瘫的患病率、发病率、患者特征与结局。2016年标准化患病率为每10万人13.8例,标准化发病率从2004年每10万人年1.5例升至2016年1.9例。糖尿病性胃轻瘫患者诊断后死亡风险显著高于特发性胃轻瘫(校正HR 1.9,95%CI 1.2至3.0)。
要点
- 2016年胃轻瘫标准化患病率为每10万人13.8例(95%CI 12.6至15.1)。
- 标准化发病率从2004年每10万人年1.5例升至2016年1.9例。
- 糖尿病性胃轻瘫诊断后死亡风险高于特发性胃轻瘫,校正HR 1.9(95%CI 1.2至3.0)。
核心结论
- 据作者所知,这是欧洲首个提供胃轻瘫流行病学与结局数据的基于人群的研究。
- 需要进一步研究以充分理解影响胃轻瘫患者结局与生存的因素。
研究设计与样本
- 回顾性横断面研究,使用英国临床实践研究数据链(CPRD)数据库,并链接医院统计住院患者护理数据和英国国家统计局死亡数据。
- 评估胃轻瘫的患病率与发病率,并按2017年中期英国人口估计进行年龄和性别标准化。
- 对人口学特征、病因、药物治疗和死亡率进行描述性分析。
主要发现
- 2016年全科医疗记录中胃轻瘫的标准化患病率为每10万人13.8例(95%CI 12.6至15.1)。
- 标准化发病率从2004年每10万人年1.5例(95%CI 1.1至1.8)上升至2016年每10万人年1.9例(95%CI 1.4至2.3)。
- 最常见病因为特发性(39.4%)和糖尿病性胃轻瘫(37.5%),在90%有糖尿病类型记录的患者中1型和2型糖尿病分布相似。
- 糖尿病性胃轻瘫患者诊断后死亡风险显著高于特发性胃轻瘫患者(校正HR 1.9,95%CI 1.2至3.0)。
- 31.6%的胃轻瘫患者在诊断后未接受任何公认的药物治疗。
局限性
- 需要进一步研究以充分理解影响胃轻瘫患者结局与生存的因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To generate real-world evidence for the epidemiology of gastroparesis in the UK, we evaluated the prevalence, incidence, patient characteristics and outcomes of gastroparesis in the Clinical Practice Research Datalink (CPRD) database. DESIGN: This was a retrospective, cross-sectional study. Prevalence and incidence of gastroparesis were evaluated in the CPRD database, with linkage to Hospital Episodes Statistics Admitted Patient Care and Office for National Statistics mortality data. Prevalence and incidence were age and sex standardised to mid-2017 UK population estimates. Descriptive analyses of demographics, aetiologies, pharmacological therapies and mortality were conducted. RESULTS: Standardised prevalence of gastroparesis, as documented in general practice records, was 13.8 (95% CI 12.6 to 15.1) per 100 000 persons in 2016, and standardised incidence of gastroparesis rose from 1.5 (95% CI 1.1 to 1.8) per 100 000 person-years in 2004 to 1.9 (95% CI 1.4 to 2.3) per 100 000 person-years in 2016. The most common disease aetiologies were idiopathic (39.4%) and diabetic gastroparesis (37.5%), with a similar distribution of type 1 and type 2 diabetes among the 90% who had type of diabetes documented. Patients with diabetic gastroparesis had a significantly higher risk of mortality than those with idiopathic gastroparesis after diagnosis (adjusted HR 1.9, 95% CI 1.2 to 3.0). Of those with gastroparesis, 31.6% were not offered any recognised pharmacological therapy after diagnosis. CONCLUSION: This is, to our knowledge, the first population-based study providing data on epidemiology and outcomes of gastroparesis in Europe. Further research is required to fully understand the factors influencing outcomes and survival of patients with gastroparesis.
引用
- Ye Y, Jiang B, Manne S, et al. Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. Gut. 2020. PMID: 32493829. doi:10.1136/gutjnl-2020-321277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。